Pharmacogenomics is the study of the relationship between genes and the drug response in humans. The pharmacogenomics market is driven by significant growth in the pharmaceutical sector. According to The European Federation of Pharmaceutical Industries and Associations’ Key Data 2019, the pharmaceutical sector in Europe was valued at US$ 139, 287 million in 2000, which increased to US$ 284, 028 million (est.) in 2018.
An increasing number of drug development activities is expected to aid in the growth of the pharmacogenomics market. In April 2021, Vertex received European Commission label extension approval for triple combination cystic fibrosis treatment Kaftrio, extending its use for the ‘majority of patients aged 12 years and older in the U.K, Germany, and other European nations. The field of pharmacogenomics now encompasses many types of research and studies. Some of these are focused on drug development, particularly in the area of genetic disorders of various types. Some studies look at how pharmacogenomics can impact public health, focusing on its impact on preventative measures such as the use of vaccines. These studies continue to provide insight into how this new area of drug development can benefit society.
One of the areas of great interest in pharmacogenomics right now is to study the role of genetic differences in human diseases. This has brought scientists a step closer to perhaps figuring out the origins of diseases as well as how to prevent or treat them. For some time, geneticists have been able to sequence the DNA of various cells and organisms. They then used this information to map the genetic differences between different organisms. This has provided them with a rich source of information about the genetic makeup of humans... Read more